Figure S1

A

B

C

D

A

Control
ATO
0.5\mu M
Control
ATO
0.5\mu M

B

Control
ATO
0.5\mu M
Control
ATO
0.5\mu M

C

Control
gilteritinib
2.5nM
Control
gilteritinib
2.5nM

D

Control
gilteritinib
2.5nM
Control
gilteritinib
2.5nM
Fig. S1 Analysis on FLT3 of 160KD and 130KD in ATO and Gilteritinib treated MV4-11 and MOLM13 cells. A-B MV4-11 and MOLM13 cells were treated with ATO (0.5µM) for 48h and data of protein levels of FLT3 are shown as the mean±SD. C-D MV4-11 and MOLM13 cells were treated with Gilteritinib (2.5nM) for 48h and data of protein levels of FLT3 are shown as the mean±SD. *P<0.05.
Figure S2

A

**MV4-11**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Gilteritinib 2.5nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

**MV4-11**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Gilteritinib 2.5nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

**MOLM13**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Gilteritinib 2.5nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D

**MOLM13**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>Gilteritinib 2.5nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>USP10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Fig. S2 USP10 protein was not affected by Gilteritinib. A-D, MV4-11 and MOLM13 cells were treated with Gilteritinib (2.5nM) for 48h and protein levels of USP10 were determined by western blot. Data are shown as the mean±SD.